相关实验视频

Updated: Jul 20, 2025

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

An Orthotopic Model of Serous Ovarian Cancer in Immunocompetent Mice for in vivo Tumor Imaging and Monitoring of Tumor Immune Responses

Published on: November 28, 2010

免疫检查点作为上卵巢癌的潜在治疗生物标志物

Azza Habel¹, Xu Weili², Mariem Hadj Ahmed¹

¹Laboratory of Mycology, Pathologies, and Biomarkers (LR16ES05), Faculty of Sciences of Tunis, University of Tunis El Manar, Tunis, Tunisia.

The International journal of biological markers

|July 31, 2023

概括

七个免疫检查点 (BTLA,CD40,CD80/B7-1,GITRL,LAG-3,TIM-3,TLR-2) 与较高的上皮卵巢癌 (EOC) 风险有关. 四个免疫检查点 (CD40,HVEM,PD-1,PD-L1) 可以预测EOC患者的化疗耐药性.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
生物标志物发现发现

背景情况:

表皮卵巢癌 (EOC) 是妇科癌症死亡的主要原因.
由于无症状的早期阶段,晚期诊断很常见,需要新的诊断生物标志物.
瘤微环境媒介可能会影响EOC进展和治疗耐药性.

研究的目的:

调查免疫检查点作为EOC的潜在治疗学生物标志物.
确定与EOC风险和化疗耐药性相关的免疫检查点.

主要方法:

在EOC患者和健康对照中测量了16个免疫检查点的血清水平.
使用了MILLIPLEX MAP人类免疫瘤检查点蛋白质磁珠面板.
统计分析将免疫检查点水平与EOC状态和化疗反应相关联.

主要成果:

七个免疫检查点 (BTLA,CD40,CD80/B7-1,GITRL,LAG-3,TIM-3,TLR-2) 在EOC患者和对照人群中显示出不同的表达.
在血清免疫检查点水平和它们的连接物之间观察到正相关性.
四个检查点 (CD40,HVEM,PD-1,PD-L1) 与对Taxol-化疗的耐药性有关,AUC>0.7.7.

结论:

七个免疫检查点 (BTLA,CD40,CD80/B7-1,GITRL,LAG-3,TIM-3,TLR-2) 的一个小组与EOC风险增加有关.
第二个由四个免疫检查点 (CD40,HVEM,PD-1,PD-L1) 组成的小组可以帮助识别高风险的化学疗法耐药性EOC患者.

关键词:

卵巢上皮癌是卵巢癌的表皮癌.免疫检查点是一个检查点.卢米内克斯 (Luminex) 公司预测生物标志物预测生物标志物

更多相关视频

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

相关概念视频

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...